Technology

Radius Health

$21.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Radius Health and other stocks, options, and ETFs commission-free!

About RDUS

Radius Health, Inc. Common Stock, also called Radius Health, is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes abaloparatide transdermal patch for potential use in osteoporosis; and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Waltham, MA. The listed name for RDUS is Radius Health, Inc. Common Stock.

CEO
George Kelly Martin
Employees
383
Headquarters
Waltham, Massachusetts
Founded
2003
Market Cap
1.01B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
588.73K
High Today
$22.33
Low Today
$21.01
Open Price
$21.66
Volume
572.84K
52 Week High
$23.30
52 Week Low
$10.15

Collections

RDUS Earnings

-$0.87
-$0.53
-$0.19
$0.15
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 25, Pre-Market

You May Also Like

XOUT
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure